Contineum Therapeutics is a clinical-stage biopharmaceutical company developing small molecule drug candidates for neurology, inflammation, and immunology (NI&I) indications. The company's lead asset, PIPE-791, is a brain-penetrant lysophosphatidic acid 1 receptor (LPA1R) antagonist in development for idiopathic pulmonary fibrosis (IPF) and chronic pain. A second candidate, PIPE-307, is a selective muscarinic type 1 receptor (M1R) inhibitor being developed for major depressive disorder and relapse-remitting multiple sclerosis in collaboration with J&J. Contineum retains worldwide rights to its LPA1R programs and discovery portfolio, while J&J holds development and commercialization rights for PIPE-307. The company conducts clinical trials globally, including a Phase 2 trial for IPF and Phase 1b studies for chronic pain.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage contineum-tx.com
Sector Healthcare IR page ir.contineum-tx.com
Tags
small molecule drugs, neurology, inflammation, immunology, idiopathic pulmonary fibrosis, chronic pain, major depressive disorder, multiple sclerosis, lpa1r antagonist, m1r inhibitor, PIPE-791, PIPE-307, JNJ-89495120, CTX-343, PROPEL-IPF, Moonlight-1, VISTA
Press page —

Metrics

Valuation  
Market cap $ 515.197M
Market cap (USD) $ 515.197M
P/E -7.63
PEG —
P/BV 2.10
P/S 10.30
P/OCF -9.93
P/FCF -9.86
Dividend yield —
Turnover / mcap —
Returns  
ROE -26.1%
ROI -31.4%
ROIC -26.7%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 5
Quality score -75.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Revenue — 0 50M 0 0
Net profit -59.978M -42.258M 22.72M -24.253M -29.001M
Free cash flow -55.543M -33.359M 18.935M -20.239M -26.434M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Share price 11.43 14.65 — — —
Price performance 12m -0.22 — — — —

Filed figures

Figure Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) 572,000 6.26M 8.25M
Cash and deposits (USD) 15.5M 21.9M 75.6M
Right-of-use assets (USD) 719,000 5.47M 7.64M
Cash flow detail
Operating cash flow (USD) 19.3M -32.8M -55.3M
Purchases of property, plant and equipment (USD) -414,000 -514,000 -231,000
Change in payables (cash effect) (USD) 0.00 1.14M -869,000
Interest paid (cash effect) (USD) -150,000 0.00 —
Income taxes paid (cash effect) (USD) -450,000 0.00 -1,000
Share-based compensation (USD) 2.22M 6.8M 10M
Free cash flow (OCF - PPE - intangibles) (USD) 18.9M -33.4M -55.5M
Income detail
Research and development expense (USD) 27.6M 38.4M 51.5M
Total comprehensive income (USD) 22.9M -42.3M -59.8M
Comprehensive income to owners (USD) 22.9M -42.3M -59.8M
Reported Mar 6, 2025 Mar 6, 2025 Mar 5, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

SAN DIEGO – November 3, 2026 – Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today reported its third-quarter 2026 financial results.

“Lysophosphatidic acid 1 receptor (LPAR1) antagonism as a treatment approach for pulmonary fibrosis has exceptionally strong clinical validation with multiple trials successfully completed including more than 1,600 patients,” said Carmine Stengone, CEO, Contineum Therapeutics. “We believe the LPAR1 class can be the ideal backbone for combination treatments. Our LPAR1 antagonist, PIPE-791, is potentially differentiated in key ways including a favorable safety and tolerability profile, sustained target engagement which we believe has the potential for improved efficacy, and superior convenience in a one-time daily, low oral dose with no titration required for patients.”

Stengone continued, “We continue to expand our footprint for PROPEL-IPF, with over 100 sites now online in 16 countries to facilitate a steady pace of enrollment.

October 29, 2026

PDF Version

SAN DIEGO--(BUSINESS WIRE)--Oct. 29, 2026-- Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that management is scheduled to present at the Stifel 2026 Healthcare Conference on Thursday, November 12th at 8:40 a.m. ET.

An audio webcast of the fireside chat can be accessed on the Investors section of Contineum’s website. A webcast replay will also be available.

About Contineum Therapeutics

Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for inflammatory and fibrotic diseases with significant unmet need. PIPE-791, an LPA1 receptor antagonist, is in clinical development for idiopathic pulmonary fibrosis and chronic pain. PIPE-307 is a selective inhibitor of the M1 receptor in clinical development by Johnson & Johnson for major depressive disorder. For more information, please visit www.contineum-tx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261029292205/en/

Steve Kunszabo Contineum Therapeutics Senior Director, Investor Relations & Corporate Communications 858-649-1158 [email protected]

Source: Contineum Therapeutics, Inc.

Scroll to top

September 14, 2026

PDF Version

  • Phase 2 MOONLIGHT-1 trial did not meet its primary efficacy endpoint

  • Analyses of the data, including prespecified exploratory endpoints, are ongoing

SAN DIEGO--(BUSINESS WIRE)--Sep. 14, 2026-- Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that the MOONLIGHT-1 trial did not achieve its primary efficacy endpoint. The trial evaluated improvement from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Day 5 compared with placebo. JNJ-5120/PIPE-307 was well-tolerated with no new safety signals.

JNJ-5120/PIPE-307 is being developed by Johnson & Johnson under a global license and development agreement. Johnson & Johnson continues to evaluate the trial data, including data related to prespecified exploratory endpoints, and assess the totality and clinical relevance of the findings to inform next steps for JNJ-5120/PIPE-307.

The Phase 2, MOONLIGHT-1 study is a randomized, double-blind, multicenter, placebo-controlled, proof-of-concept trial evaluating the efficacy, safety and tolerability of JNJ-5120/PIPE-307 as monotherapy in adult participants with MDD. More information on this trial can be found at https://clinicaltrials.gov (NCT06785012).

About Contineum Therapeutics

Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for inflammatory and fibrotic diseases with significant unmet need. Contineum is advancing a pipeline of internally-developed programs with multiple drug candidates now in clinical trials. PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis and chronic pain. PIPE-307 is a selective inhibitor of the M1 receptor in clinical development by Johnson & Johnson for major depressive disorder. For more information, please visit www.contineum-tx.com.

Forward-Looking Statements

Certain statements contained in this press release, other than historical information, constitute forward-looking statements within the meaning of the federal securities laws. Forward-looking statements include, but are not limited to, implied or express statements regarding the pharmacological properties, safety, tolerability, clinical response and efficacy of JNJ-5120/PIPE-307 and statements regarding Johnson &Johnson’s plans to further assess the results of its Phase 2, MOONLIGHT-1 study and to consider next steps for JNJ-5120/PIPE-307. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond the Company’s control and may cause its actual results, events, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties, include, but are not limited to, the following: the Company is heavily dependent on the success of PIPE-791 and PIPE-307, both of which are in the early stages of clinical development, and neither of these drug candidates may progress through clinical development or receive regulatory approval; the results of preclinical studies and clinical trials, including those conducted by third parties, may not be predictive of future results and unexpected adverse side effects or inadequate efficacy of the Company’s drug candidates may limit their development, regulatory approval and/or commercialization; the timing and outcome of research, development and regulatory review is uncertain; the FDA or comparable foreign regulatory authorities may disagree as to the design or implementation of our proposed clinical trials; clinical trials and preclinical studies may not proceed at the time or in the manner expected, or at all; the Company may use its capital resources sooner than expected and they may be insufficient to allow the Company to achieve its anticipated milestones; the potential for the Company’s programs and prospects to be negatively impacted by developments relating to the Company’s competitors, including the results of studies or regulatory determinations relating to the Company’s competitors; risks associated with reliance on third parties to successfully conduct clinical trials; the Company’s reliance, pursuant to a global license and development agreement, upon Janssen Pharmaceutica NV, a Johnson & Johnson company, to develop, in its sole discretion, PIPE-307 for MDD or for any other indication; the restrictions contained in the Company’s global license and development agreement with Janssen Pharmaceutica NV limiting the Company’s access to, and restricting the Company from disclosing, certain information regarding the development of PIPE-307; the Company has incurred significant operating expenses since inception and it expects that its operating expenses will continue to significantly increase for the foreseeable future; the Company’s ability to operate in a competitive industry and compete successfully against competitors that have greater resources than the Company does; the Company may be unable to obtain, maintain and enforce intellectual property protection for its technology and drug candidates; and unstable market and economic conditions and military conflicts may adversely affect the Company’s business and financial condition and the broader economy and biotechnology industry. Additional risks and uncertainties that could affect the Company’s business, operations and results are included under the captions, “Risk Factors” and "Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company's periodic filings and in other filings that the Company makes with the Securities and Exchange Commission (SEC) from time to time, which are available on the Company’s website at www.contineum-tx.com under the Investor section and on the SEC’s website at www.sec.gov. Accordingly, readers should not rely upon forward-looking statements as predictions of future events. Except as required by applicable law, the Company undertakes no obligation to update publicly or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260914716616/en/

Steve Kunszabo Contineum Therapeutics Senior Director, Investor Relations & Corporate Communications 858-649-1158 [email protected]

Source: Contineum Therapeutics, Inc.

Scroll to top

Prompts

Contineum Therapeutics, Inc. (ticker CTNM), listed in United States.

ETFs Holding Contineum Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
AVSC 0.02% 59,501 $ 575.375K Nov 16, 2026
DFAS 0.00% 106,132 $ 1.038M Nov 12, 2026
DXUV 0.00% 4,300 $ 42.054K Nov 12, 2026
DCOR 0.00% 28,878 $ 282.427K Nov 12, 2026
DFAC 0.00% 43,790 $ 428.266K Nov 12, 2026
DFSU 0.00% 293 $ 2,865.54 Nov 12, 2026